149 related articles for article (PubMed ID: 25471028)
1. Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test.
Dupont B; Mariotte D; Clarisse B; Galais MP; Bouhier-Leporrier K; Grellard JM; Le Mauff B; Reimund JM; Gervais R
Future Oncol; 2014 Nov; 10(14):2133-40. PubMed ID: 25471028
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab infusion reactions: French pharmacovigilance database analysis.
Grandvuillemin A; Disson-Dautriche A; Miremont-Salamé G; Fourrier-Reglat A; Sgro C;
J Oncol Pharm Pract; 2013 Jun; 19(2):130-7. PubMed ID: 23154574
[TBL] [Abstract][Full Text] [Related]
3. Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.
Dupont B; Mariotte D; Dugué AE; Clarisse B; Grellard JM; Babin E; Chauffert B; Dakpé S; Moldovan C; Bouhier-Leporrier K; Reimund JM; Di Fiore F; Zanetta S; Mailliez A; Do P; Peytier A; Galais MP; Florescu C; Schott R; Le Mauff B; Gervais R
Br J Clin Pharmacol; 2017 Mar; 83(3):623-631. PubMed ID: 27662818
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions.
Maier S; Chung CH; Morse M; Platts-Mills T; Townes L; Mukhopadhyay P; Bhagavatheeswaran P; Racenberg J; Trifan OC
Cancer Med; 2015 Jan; 4(1):36-42. PubMed ID: 25296628
[TBL] [Abstract][Full Text] [Related]
5. Skin prick test and basophil reactivity to cetuximab in patients with IgE to alpha-gal and allergy to red meat.
Michel S; Scherer K; Heijnen IA; Bircher AJ
Allergy; 2014 Mar; 69(3):403-5. PubMed ID: 24372137
[TBL] [Abstract][Full Text] [Related]
6. A novel approach to predict cetuximab-induced hypersensitivity reaction: detection of drug-specific IgE on basophils.
Iwamoto T; Okamoto A; Ishinaga H; Shimizu K; Gayle AA; Arai N; Takeuchi K; Okuda M
Cancer Med; 2016 Jun; 5(6):1004-12. PubMed ID: 26880699
[TBL] [Abstract][Full Text] [Related]
7. Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital.
Keating K; Walko C; Stephenson B; O'Neil BH; Weiss J
J Oncol Pharm Pract; 2014 Dec; 20(6):409-16. PubMed ID: 24243920
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.
Hopps S; Medina P; Pant S; Webb R; Moorman M; Borders E
J Oncol Pharm Pract; 2013 Sep; 19(3):222-7. PubMed ID: 23135806
[TBL] [Abstract][Full Text] [Related]
9. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.
Vultaggio A; Matucci A; Nencini F; Pratesi S; Parronchi P; Rossi O; Romagnani S; Maggi E
Allergy; 2010 May; 65(5):657-61. PubMed ID: 19951375
[TBL] [Abstract][Full Text] [Related]
10. Low rate of cetuximab hypersensitivity reactions in Northeast Tennessee: An Appalachian effect?
Adams CB; Street DS; Crass M; Bossaer JB
J Oncol Pharm Pract; 2016 Dec; 22(6):784-789. PubMed ID: 26590031
[TBL] [Abstract][Full Text] [Related]
11. Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center.
Hansen NL; Chandiramani DV; Morse MA; Wei D; Hedrick NE; Hansen RA
J Oncol Pharm Pract; 2011 Jun; 17(2):125-30. PubMed ID: 20147576
[TBL] [Abstract][Full Text] [Related]
12. Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis.
Mariotte D; Dupont B; Gervais R; Galais MP; Laroche D; Tranchant A; Comby E; Bouhier-Leporrier K; Reimund JM; Le Mauff B
MAbs; 2011; 3(4):396-401. PubMed ID: 21654207
[TBL] [Abstract][Full Text] [Related]
13. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity reactions during treatment with biological agents.
Puxeddu I; Caltran E; Rocchi V; Del Corso I; Tavoni A; Migliorini P
Clin Exp Rheumatol; 2016; 34(1):129-32. PubMed ID: 26751942
[TBL] [Abstract][Full Text] [Related]
15. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.
Chung CH; Mirakhur B; Chan E; Le QT; Berlin J; Morse M; Murphy BA; Satinover SM; Hosen J; Mauro D; Slebos RJ; Zhou Q; Gold D; Hatley T; Hicklin DJ; Platts-Mills TA
N Engl J Med; 2008 Mar; 358(11):1109-17. PubMed ID: 18337601
[TBL] [Abstract][Full Text] [Related]
17. Anaphylaxis to diclofenac: nine cases reported to the Allergy Vigilance Network in France.
Picaud J; Beaudouin E; Renaudin JM; Pirson F; Metz-Favre C; Dron-Gonzalvez M; Moneret-Vautrin DA
Allergy; 2014 Oct; 69(10):1420-3. PubMed ID: 24931488
[TBL] [Abstract][Full Text] [Related]
18. Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab.
Serrier J; Davy JB; Dupont B; Clarisse B; Parienti JJ; Petit G; Khoy K; Ollivier Y; Gervais R; Mariotte D; Le Mauff B
BMC Cancer; 2023 Jan; 23(1):32. PubMed ID: 36624467
[TBL] [Abstract][Full Text] [Related]
19. Diagnosing hypersensitivity reactions to cephalosporins in children.
Romano A; Gaeta F; Valluzzi RL; Alonzi C; Viola M; Bousquet PJ
Pediatrics; 2008 Sep; 122(3):521-7. PubMed ID: 18762521
[TBL] [Abstract][Full Text] [Related]
20. Management of hypersensitivity reactions to Tocilizumab.
Tétu P; Hamelin A; Moguelet P; Barbaud A; Soria A
Clin Exp Allergy; 2018 Jun; 48(6):749-752. PubMed ID: 29603809
[No Abstract] [Full Text] [Related]
[Next] [New Search]
